Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Swe Mar Linn"'
Autor:
Jennifer White, Mohamed Elemary, Swe Mar Linn, Igor Novitzky-Basso, Samantha Culos, Sui Keat Tan, Kate Kelly, Uday Deotare, Anargyros Xenocostas, Nada Hamad, Arjun Law, Rajat Kumar, Dennis Dong Hwan Kim
Publikováno v:
Transplantation and cellular therapy.
While ruxolitinib is emerging as the treatment of choice for steroid refractory/dependent chronic graft vs host disease (cGVHD) based on randomized control trial data, there is relatively little real world data published on ruxolitninb for this indic
Autor:
Alistair Murray, Swe Mar Linn, Benoit Yu, Igor Novitzky-Basso, Jonas Mattsson, Mohamed Elemary, Jennifer White, Christopher Lemieux, Kareem Jamani, Dennis Kim
Publikováno v:
Blood. 140:7662-7663
Publikováno v:
Transplantation and Cellular Therapy. 29:S328
Autor:
Jeffrey H. Lipton, Fotios V. Michelis, Wilson Lam, Carol Chen, Auro Viswabandya, Zeyad Al-Shaibani, Arjun Datt Law, Rajat Kumar, Armin Gerbitz, Ivan Pasic, Swe Mar Linn, Dennis Dong Hwan Kim, Jonas Mattsson, Ram V Nampoothiri
Publikováno v:
Hematology/Oncology and Stem Cell Therapy.
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL). METHODS We analyzed the outcomes of 93 patients (median age: 52 years) who underwe
Autor:
Dennis Dong Hwan Kim, Swe Mar Linn, Jennifer White, Igor Novitzky-Basso, Omar Abduljalil, Nada Hamad, Arjun Law
Publikováno v:
Blood. 136:45-47
Background Several agents have been investigated for beyond second-line treatment of chronic graft-versus-host disease (GVHD). Ruxolitinib has been recently approved for steroid-refractory acute GVHD, while a prospective randomized study is ongoing t
Autor:
Jennifer White, Swe Mar Linn, Anargyros Xenocostas, Sui Tan, Arjun Law, Igor Novitzky-Basso, Samantha Culos, Mohamed Elemary, Dennis Dong Hwan Kim, Nada Hamad
Publikováno v:
Blood. 138:1805-1805
Background The REACH3 study has reported greater overall response and failure-free survival (FFS) with Ruxolitinib (RUX) as 2 nd line therapy for steroid-refractory chronic graft versus host disease (cGVHD) in comparison to best available therapy (BA
Autor:
Auro Viswabandya, Christopher J. Patriquin, Swe Mar Linn, Ivan Pasic, Dennis Dong Hwan Kim, Jonas Mattsson, David Barth, Wilson Lam, Arjun Law, Armin Gerbitz, Igor Novitzky-Basso, Rajat Kumar, Fotios V. Michelis, Jeffrey H. Lipton
Publikováno v:
Blood. 138:1806-1806
*DB and DK contributed to the work equally. Background Extracorporeal photopheresis (ECP) is a recommended second or later line of therapy for chronic GVHD (cGVHD), and is beneficial not only because of increased response but also for its lack of adv
Autor:
Dennis Dong Hwan Kim, Jonas Mattsson, Arjun Law, Fotios V. Michelis, David Barth, Rajat Kumar, Elizabeth Shin, Wilson Lam, Jeffrey H. Lipton, Armin Gerbitz, Auro Viswabandya, Igor Novitzky-Basso, Ivan Pasic, Christopher J. Patriquin, Swe Mar Linn
Publikováno v:
Blood. 138:3896-3896
*DB and DK contributed to the work equally Background Prospective randomized controlled data comparing extracorporeal photopheresis (ECP) to other treatments for chronic graft vs host disease (cGvHD) as third-line or later therapy are limited, despit
Autor:
Anargyros Xenocostas, Arjun Law, Igor Novitzky-Basso, Jennifer White, Mohamed Elemary, Jonas Mattsson, Dennis Dong Hwan Kim, Nada Hamad, Rajat Kumar, Sui Tan, Swe Mar Linn, Samantha Culos
Publikováno v:
Blood. 138:3905-3905
Background The REACH3 trial evaluating Ruxolitinib (RUX) treatment for steroid-refractory chronic GVHD concluded that RUX leads to significantly greater overall response and failure-free survival (FFS) than best available therapies (NEJM 2021). We re
Autor:
Fotios V. Michelis, Omar Abduljalil, Zeyad Al-Shaibani, Arjun Law, Igor Novitzky-Basso, Swe Mar Linn, Ivan Pasic, Auro Viswabandya, Rajat Kumar, Jeffrey H. Lipton, Ram V Nampoothiri, Armin Gerbitz, Jonas Mattson, Wilson Lam, Dennis Dong Hwan Kim
Publikováno v:
Blood. 136:17-18
Background Chronic graft-versus-host-disease (cGVHD) is one of the main causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HCT). Tyrosine kinase inhibitor such as Ruxolitinib, Ibrutinib and Imatinib showed a p